Tvardi Therapeutics, Inc. (TVRD)

NASDAQ: TVRD · Real-Time Price · USD
22.85
+0.72 (3.25%)
At close: Jul 10, 2025, 4:00 PM
22.67
0.00 (0.00%)
Pre-market: Jul 11, 2025, 8:00 AM EDT
3.25%
Market Cap 212.21M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 9.36M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19,929
Open 21.87
Previous Close 22.13
Day's Range 21.86 - 22.85
52-Week Range 8.13 - 34.31
Beta n/a
Analysts Strong Buy
Price Target 58.50 (+165.51%)
Earnings Date Aug 21, 2025

About TVRD

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country United States
Stock Exchange NASDAQ
Ticker Symbol TVRD
Full Company Profile

Analyst Summary

According to 4 analysts, the average rating for TVRD stock is "Strong Buy." The 12-month stock price target is $58.5, which is an increase of 165.51% from the latest price.

Price Target
$58.5
(165.51% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

Newly public Tvardi Therapeutics, Inc. TVRD is capturing investor attention following its recent reverse merger with Cara Therapeutics, Inc.

4 weeks ago - Benzinga

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

6 weeks ago - Business Wire

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

7 weeks ago - Business Wire

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical- stage biopharmaceutical company focused on the development of novel, oral, sma...

2 months ago - Business Wire

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

2 months ago - Business Wire

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases.

Other symbols: CARA
3 months ago - GlobeNewsWire